Pelvic Intraoperative Neuromonitoring Prevents Dysfunction in Patients With Rectal Cancer
Authors:
- Werner KneistWKWerner Kneist
- Michael GhadimiMGMichael Ghadimi
- Norbert RunkelNRNorbert Runkel
- Thomas MoestaTMThomas Moesta
- Stephan CoerperSCStephan Coerper
- Claudia BeneckeCBClaudia Benecke
- Daniel W. KauffDKDaniel W. Kauff
- Stephan GretschelSGStephan Gretschel
- Ines GockelInes Gockel
- Boris Jansen-WinkelnBoris Jansen-Winkeln
- Hauke LangHLHauke Lang
- Stanislav GorbulevSGStanislav Gorbulev
Open Access
- 22 September 2022
- journal article
- research article
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 277 (4) , e737-e744
Abstract
Objective: This NEUROmonitoring System (NEUROS) trial assessed whether pelvic intraoperative neuromonitoring (pIONM) could improve urogenital and ano-(neo-)rectal functional outcomes in patients who underwent total mesorectal excisions (TMEs) for rectal cancer. Background: High-level evidence from clinical trials is required to clarify the benefits of pIONM. Methods: NEUROS was a 2-arm, randomized, controlled, multicenter clinical trial that included 189 patients with rectal cancer who underwent TMEs at 8 centers, from February 2013 to January 2017. TMEs were performed with pIONM (n=90) or without it (control, n=99). The groups were stratified according to neoadjuvant chemoradiotherapy and sex, with blocks of variable length. Data were analyzed according to a modified intention-to-treat protocol. The primary endpoint was a urinary function at 12 months after surgery, assessed with the International Prostate Symptom Score, a patient-reported outcome measure. Deterioration was defined as an increase of at least 5 points from the preoperative score. Secondary endpoints were sexual and anorectal functional outcomes, safety, and TME quality. Results: The intention-to-treat analysis included 171 patients. Marked urinary deterioration occurred in 22/171 (13%) patients, with significantly different incidence between groups (pIONM: n=6/82, 8%; control: n=16/89, 19%; 95% confidence interval, 12.4–94.4; P=0.0382). pIONM was associated with better sexual and ano-(neo)rectal function. At least 1 serious adverse event occurred in 36/88 (41%) in the pIONM group and 53/99 (54%) in the control group, none associated with the study treatment. The groups had similar TME quality, surgery times, intraoperative complication incidence, and postoperative mortality. Conclusion: pIONM is safe and has the potential to improve functional outcomes in rectal cancer patients undergoing TME.Keywords
This publication has 28 references indexed in Scilit:
- Rectal Cancer-Associated Urinary Dysfunction: a ReviewCurrent Bladder Dysfunction Reports, 2015
- A prospective video-controlled study of genito-urinary disorders in 35 consecutive laparoscopic TMEs for rectal cancerSurgical Endoscopy, 2014
- Patient-reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a randomized trial (COLOR II)British Journal of Surgery, 2014
- Is intraoperative neuromonitoring associated with better functional outcome in patients undergoing open TME?European Journal of Surgical Oncology, 2013
- Long-term Results of Rectal Cancer Surgery with a Systematical Operative ApproachAnnals of Surgical Oncology, 2013
- Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2)Radiotherapy and Oncology, 2009
- The LANN Technique to Reduce Postoperative Functional Morbidity in Laparoscopic Radical Pelvic SurgeryJournal of the American College of Surgeons, 2005
- The Efficacy of a Nerve Stimulator (Cavermap®) to Enhance Autonomic Nerve Identification and Confirm Nerve Preservation During Total Mesorectal ExcisionDiseases of the Colon & Rectum, 2004
- Intraoperative identification and neurophysiologic parameters to verify pelvic autonomic nerve function during total mesorectal excision for rectal cancerJournal of the American College of Surgeons, 2004
- The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?British Journal of Surgery, 1982